Bristol/Imclone Review Erbitux Pricing For Chronic Care Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb and Imclone are considering reducing the price of the oncologic Erbitux (cetuximab) for chronic care patients